Prurigo Nodularis News & ResearchDupilumab Beneficial for Adults With Prurigo NodularisAll primary and key secondary end points met in two phase 3 trials of adults with PN with ≥20 nodulesBy Elana Gotkine (HealthDay News) | May 10, 2023FDA Approves Dupixent for Prurigo NodularisThis priority review-based approval makes Dupixent the first treatment for the inflammatory skin conditionBy Physician’s Briefing Staff | September 30, 2022AAD: Dupilumab Beneficial in Adults With Prurigo NodularisSignificantly more dupilumab-treated patients achieved ≥4-point reduction in 24h Worst-Itch Numeric Rating Scale at weeks 12 and 24By Dermsquared Editorial Team | April 06, 2022